Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Lakewood-Amedex Biotherapeutics

LABT

----

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

3 Penny Stocks to Watch Today, 7/23/2026
Tip Ranks·1 day ago, 10:05 AM
LABT-13.73%ZCMD-19.08%
Top Biotech Gainers: ZCMD Surges 190%, LABT Advances On Nu-3 Progress, ARWR Hits The Targets
rttnews·1 day ago, 10:15 PM
ZCMD-19.08%DRIO+4.28%
Lakewood-Amedex Biotherapeutics surges 8% in after-hours trading
US Stock Market Update·1 day ago, 04:20 PM
LABT-13.73%
Lakewood-Amedex Biotherapeutics surges 75% in regular trading
US Stock Market Update·2 days ago, 01:51 PM
LABT-13.73%
12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga_article·2 days ago, 12:05 PM
CPHI-17.84%PMI-0.11%
Lakewood-Amedex Biotherapeutics soars 87% during regular trading on heavy volume
US Stock Market Update·2 days ago, 11:11 AM
LABT-13.73%
Lakewood-Amedex Biotherapeutics soars 212% on Nu-3 drug data
US Stock Market Update·2 days ago, 08:40 AM
LABT-13.73%
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga_article·2 days ago, 07:05 AM
JUNS-20.92%INM-7.57%
Lakewood-Amedex Biotherapeutics flags new press release available on Nu-3 resistance data
PUBT·2 days ago, 07:04 AM
LABT-13.73%
Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria | LABT Stock News
StockTitan·2 days ago, 11:02 PM
LABT-13.73%
Lakewood-Amedex Biotherapeutics makes Investor Deck public, Nu-3 Phase 2a planned with IND open
TradingView·Jul 15 at 03:23 PM
LABT-13.73%
Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel | LABT Stock News
StockTitan·Jul 14 at 11:02 PM
LABT-13.73%